Therapeutic cancer vaccine market: antigen-specific therapies lead the way

Published By Datamonitor

Targeted therapy cancer brands to achieve sales of over $42 billion by 2017

Targeted therapies have improved treatment outcomes in cancer notably, becoming the leading therapy class in the oncology market. As a result, they are expected to achieve sales of over $42 billion by 2017. Eight more marketed brands are set to achieve blockbuster status over the 10-year forecast period, driven by the persistent unmet need that still exists across a number of tumor types.

Published By Datamonitor

Targeted therapies promise new hope for brain cancer patients

While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. However, significant progress is being made with research into the disease and innovative new therapies may be able to improve survival rates for brain cancer patients.

Published By Datamonitor

Synta/GlaxoSmithKline: skin cancer drug setback

Following an analysis by independent safety monitors, Synta Pharmaceuticals has been forced to halt a pivotal Phase III trial of elesclomol in advanced melanoma. While this news is particularly disappointing for the melanoma market, where a significant unmet need exists, the setback also presents ominous consequences for Synta.

Published By Datamonitor

Solid tumor market: potential lies in targeted therapies

Published By Datamonitor

Roche: novel Herceptin formulation promises greater convenience

Having stepped up lifecycle management for its leading breast cancer monoclonal antibody, Herceptin, Roche hopes to encourage uptake of a more convenient formulation of the drug. This strategy could help to conserve its share of an increasingly competitive market, but may be challenging to implement due to concerns over compliance and financial incentives to prescribe intravenous cancer drugs.

Published By Datamonitor

Roche: implementing cuts to maintain its strong fiscal position

In light of R&D setbacks and slowing sales growth, Roche has outlined a number of cost-saving initiatives, including the termination of 4,800 jobs. Despite a challenging year, Roche's above-average operating profit in 2009 is expected to be maintained, and these new initiatives are expected to result in cost savings of up to $2.4bn per year, leaving the company in a strong financial position.

Published By Datamonitor

Roche/Genentech/Biogen Idec: Rituxan delays need for new therapy in follicular lymphoma

New data show that immediate treatment with Rituxan provides an impressive reduction in follicular lymphoma progression rates. These results could lead to a change in the management of newly diagnosed asymptomatic follicular lymphoma patients and increased uptake of Rituxan in the seven major markets.

Published By Datamonitor

Prostate cancer: new study could clear up vitamin E debate

Published By Datamonitor

Pfizer: breakthrough for neuroendocrine tumor therapy

Pfizer has announced that a Phase III trial of Sutent in advanced pancreatic neuroendocrine tumors has reached its primary endpoint of improved progression-free survival. Given the niche, underserved nature of the advanced pancreatic neuroendocrine market, seeking a line extension in this indication may be a successful strategy for the company.

Published By Datamonitor